Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of CriPec docetaxel in advanced solid tumours
NL-OMON44828Phase 1Recruiting
- Sponsor
- Cristal Therapeutics
- Start
- Oct 2015
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of docetaxel in Nonhematologic neoplasms (3 arms), sponsored by Cristal Therapeutics. Primary endpoints: Dose-limiting toxicities, Pharmacokinetics of total and released docetaxel and 4 more. Started Oct 2015; status: recruiting.
02
Drugs
docetaxel
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON44828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44828.